Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.

Original languageEnglish (US)
JournalMycopathologia
DOIs
StateAccepted/In press - Jun 26 2015

Keywords

  • Anti-TNF
  • Delayed-release tablets
  • Mucormycosis
  • Posaconazole

ASJC Scopus subject areas

  • Plant Science
  • Agronomy and Crop Science
  • Applied Microbiology and Biotechnology
  • Microbiology
  • veterinary (miscalleneous)

Fingerprint Dive into the research topics of 'Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole'. Together they form a unique fingerprint.

  • Cite this